tradingkey.logo

Titan Pharmaceuticals Inc

TTNP

3.850USD

-0.140-3.51%
Horarios del mercado ETCotizaciones retrasadas 15 min
3.52MCap. mercado
PérdidaP/E TTM

Titan Pharmaceuticals Inc

3.850

-0.140-3.51%
Más Datos de Titan Pharmaceuticals Inc Compañía
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Información de la empresa
Símbolo de cotizaciónTTNP
Nombre de la empresaTitan Pharmaceuticals Inc
Fecha de salida a bolsaJan 18, 1996
Director ejecutivoMr. Weei Jye Chay
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 18
DirecciónSuite 505
CiudadSAN FRANCISCO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94080
Teléfono14152444990
Sitio Webhttps://www.titanpharm.com/
Símbolo de cotizaciónTTNP
Fecha de salida a bolsaJan 18, 1996
Director ejecutivoMr. Weei Jye Chay
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
Independent Director
Independent Director
3.31K
--
Mr. Gabriel Loh
Mr. Gabriel Loh
Independent Director
Independent Director
--
--
Mr. Weei Jye Chay
Mr. Weei Jye Chay
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Brynner Chiam
Mr. Brynner Chiam
Acting Principal Financial Officer, Director
Acting Principal Financial Officer, Director
--
--
Mr. Firdauz Edmin Bin Mokhtar, CPA
Mr. Firdauz Edmin Bin Mokhtar, CPA
Independent Director
Independent Director
--
--
Mr. Francisco Osvaldo Flores Garcia
Mr. Francisco Osvaldo Flores Garcia
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
Independent Director
Independent Director
3.31K
--
Mr. Gabriel Loh
Mr. Gabriel Loh
Independent Director
Independent Director
--
--
Mr. Weei Jye Chay
Mr. Weei Jye Chay
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Brynner Chiam
Mr. Brynner Chiam
Acting Principal Financial Officer, Director
Acting Principal Financial Officer, Director
--
--
Mr. Firdauz Edmin Bin Mokhtar, CPA
Mr. Firdauz Edmin Bin Mokhtar, CPA
Independent Director
Independent Director
--
--
Mr. Francisco Osvaldo Flores Garcia
Mr. Francisco Osvaldo Flores Garcia
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 25 de jul
Actualizado: vie., 25 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Blue Harbour Asset Management L.L.C
19.99%
Choong (Choon Hau)
18.16%
Chung (Jeffrey)
11.28%
Citadel Advisors LLC
0.90%
Geode Capital Management, L.L.C.
0.52%
Other
49.15%
Accionistas
Accionistas
Proporción
Blue Harbour Asset Management L.L.C
19.99%
Choong (Choon Hau)
18.16%
Chung (Jeffrey)
11.28%
Citadel Advisors LLC
0.90%
Geode Capital Management, L.L.C.
0.52%
Other
49.15%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
29.69%
Corporation
19.99%
Hedge Fund
0.90%
Investment Advisor/Hedge Fund
0.54%
Investment Advisor
0.51%
Other
48.38%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
40
414.53K
44.46%
-42.07K
2025Q1
46
436.25K
42.35%
-38.12K
2024Q4
45
429.27K
46.95%
-32.22K
2024Q3
46
432.62K
47.32%
-13.85K
2024Q2
51
448.01K
49.00%
-8.81K
2024Q1
52
447.94K
49.00%
-53.81K
2023Q4
49
450.14K
59.78%
+330.86K
2023Q3
57
298.19K
41.35%
-95.76K
2023Q2
53
281.88K
39.24%
-113.75K
2023Q1
57
262.38K
36.64%
-134.22K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Choong (Choon Hau)
241.53K
18.16%
--
--
Apr 21, 2025
Chung (Jeffrey)
143.84K
10.81%
+143.84K
--
Mar 12, 2025
Citadel Advisors LLC
11.96K
0.9%
+11.96K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
6.91K
0.52%
--
--
May 31, 2025
The Vanguard Group, Inc.
4.10K
0.31%
--
--
May 31, 2025
Ben-Tzvi (Avraham)
3.31K
0.25%
--
--
Apr 21, 2025
UBS Financial Services, Inc.
2.59K
0.2%
-73.00
-2.74%
Mar 31, 2025
Northern Trust Investments, Inc.
129.00
0.01%
+129.00
--
Dec 31, 2023
Corecap Advisors Inc
88.00
0.01%
+88.00
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Nov 30, 2020
Merger
30<1
Nov 30, 2020
Merger
30<1
Fecha
Tipo
Relación
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Nov 30, 2020
Merger
30<1
Nov 30, 2020
Merger
30<1
Nov 30, 2020
Merger
30<1
Nov 30, 2020
Merger
30<1
KeyAI